{"count": 2, "results": [{"_id": "33681737", "pmid": 33681737, "pmcid": "PMC7910694", "title": "The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial", "journal": "EClinicalMedicine", "authors": ["Amin S", "Mallick AA", "Edwards H", "Cortina-Borja M", "Laugharne M", "Likeman M", "O'Callaghan FJK"], "date": "2021-01-14T00:00:00Z", "doi": "10.1016/j.eclinm.2020.100715", "meta_date_publication": "2021 Feb", "meta_volume": "32", "meta_issue": "", "meta_pages": "100715", "score": 50255.324, "text_hl": "We investigated whether @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ would reduce growth of @<m>DISEASE_Hamartoma</m> @DISEASE_MESH:D006222 @@@hamartomas@@@ associated with @DISEASE_Tuberous_Sclerosis @DISEASE_MESH:D014402 @@@tuberous sclerosis complex@@@.", "citations": {"NLM": "Amin S, Mallick AA, Edwards H, Cortina-Borja M, Laugharne M, Likeman M, O'Callaghan FJK. The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial EClinicalMedicine. 2021 Feb;32():100715. PMID: 33681737", "BibTeX": "@article{33681737, title={The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial}, author={Amin S and Mallick AA and Edwards H and Cortina-Borja M and Laugharne M and Likeman M and O'Callaghan FJK}, journal={EClinicalMedicine}, volume={32}, pages={100715}}"}}, {"_id": "30290005", "pmid": 30290005, "title": "The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth.", "journal": "Br J Clin Pharmacol", "authors": ["Amin S", "Lux A", "O'Callaghan F"], "date": "2019-01-01T00:00:00Z", "doi": "10.1111/bcp.13780", "meta_date_publication": "2019 Jan", "meta_volume": "85", "meta_issue": "1", "meta_pages": "37-46", "score": 50053.527, "text_hl": "Because of its effect on the @GENE_MTOR @GENE_2475 @@@mTOR@@@ pathway, there may be a role for @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in slowing or reversing growth of life-threatening @<m>DISEASE_Hamartoma</m> @DISEASE_MESH:D006222 @@@hamartomas@@@ in @DISEASE_Tuberous_Sclerosis @DISEASE_MESH:D014402 @@@tuberous sclerosis complex@@@.", "citations": {"NLM": "Amin S, Lux A, O'Callaghan F. The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. Br J Clin Pharmacol. 2019 Jan;85(1):37-46. PMID: 30290005", "BibTeX": "@article{30290005, title={The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth.}, author={Amin S and Lux A and O'Callaghan F}, journal={Br J Clin Pharmacol}, volume={85}, number={1}, pages={37-46}}"}}]}